U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07051070) titled 'Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases' on June 16.
Brief Summary: In 2025, a novel meningoencephalomyelitis associated with Vimentin IgG in cerebrospinal fluid (CSF) has been identified. Most patients exhibited progressive or recurrent episodes, characterized by prominent cerebellar ataxia, cranial nerve palsies, and pyramidal signs. The characteristic features included bilateral magnetic resonance imaging (MRI) lesions of the corticospinal tract, elevated CSF protein levels, and increased CSF cell counts. Despite receiving immunotherapy, these patients experienced significant...